Should You Buy LeMaitre Vascular, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, LeMaitre Vascular, Inc. (LMAT) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 9.3/10. At a current price of $80.24 and a market capitalization of $1.8B, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.
The short answer: 1 of 11 CirclFi valuation models project upside for LeMaitre Vascular, Inc. (LMAT) at $80.24 — the model consensus leans bearish, with a Quality Score of 9.3/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for LeMaitre Vascular, Inc. (LMAT) in 2026?
What Is the Bull Case vs the Bear Case for LeMaitre Vascular, Inc. (LMAT)?
| Bull case — $101.75 target (+26.8%) | Bear case — $19.89 target (-75.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, LeMaitre Vascular, Inc.'s quality score of 9.3/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $19.89 (-75.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $101.75 (+26.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +102.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
How Does LMAT Compare to Its Medical Instruments & Supplies Peers?
Valuation data pages: RMD · ATR · ISRG · MMSI · NNNN · WST · ATRC · MMED · CUPR
Which Other Stocks Score Like LMAT on Quality?
Closest companies to LMAT’s Quality of Company score of 9.3/10, across all industries.
- BMI — Badger Meter, Inc. (QOC 9.3) · analysis
- BZ — Kanzhun Limited (QOC 9.3) · analysis
- NEM — Newmont Corporation (QOC 9.3) · analysis
- META — Meta Platforms, Inc. (QOC 9.3) · analysis
- PH — Parker-Hannifin Corporation (QOC 9.3) · analysis
- HWM — Howmet Aerospace Inc. (QOC 9.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Instruments & Supplies Screens Does LMAT Appear In?
So Is LeMaitre Vascular, Inc. (LMAT) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on LeMaitre Vascular, Inc. at $80.24. 10/11 models flag overvaluation, median fair value sits at $43.30 (-46.0%), and the risk-reward profile appears unfavorable. Quality at 9.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. LeMaitre Vascular, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About LMAT Stock?
Should I buy LMAT stock right now?
Based on CirclFi's multi-model analysis, 1 of 11 models see upside for LMAT at $80.24. The models are divided, which means the investment case depends heavily on your assumptions about LeMaitre Vascular, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in LeMaitre Vascular, Inc.?
Key risks include: wide model disagreement (411% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.
How does LMAT compare to its competitors?
Among Medical Instruments & Supplies peers, LMAT holds a Quality Score of 9.3/10. Comparable companies include RMD (QOC 9.4), ATR (QOC 8.9), ISRG (QOC 9.4). The relative ranking helps investors identify whether LMAT offers better fundamental quality than alternatives in the same sector.
Is LMAT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LMAT's Quality Score of 9.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy LMAT at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $19.89 to $101.75. At $80.24, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for LMAT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad